PODCAST

Oncology and Hematology

ReachMD

science & medicine medicine

All Episodes

00:00:00

Virtual Tumor Board: Maximizing the Potential of...

Oncology and Hematology ·

2025/02/05

Guest: Heather McArthur, MD Guest: Margaret Gatti-Mays, MD, MPH Tune in for a deep dive into the evolving landscape of immuno-oncology (IO) in early-stage triple-negative breast cancer (TNBC). Our experts focus on identifying eligible patients for neoadjuvant and adjuvant IO regimens, understanding current and emerging treatment options, and effectively utilizing shared decision-making (SDM) techniques to tailor treatment plans. The activity also covers the importance of

00:00:00

Effective Monitoring and Management of Adverse...

Oncology and Hematology ·

2024/12/20

Host: Harry Yoon, MD Guest: Jaffer Ajani, MD This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform

00:00:00

Distinguishing Between Anti-PD-1 Agents in ESCC...

Oncology and Hematology ·

2024/12/20

Host: Jaffer Ajani, MD This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection

00:00:00

The Importance of PD-L1 Testing: Shaping the Future...

Oncology and Hematology ·

2024/12/20

Host: Harry Yoon, MD This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection

00:00:00

Poster Pearl: Treating ER+/HER2- mBC with Elacestrant...

Oncology and Hematology ·

2024/11/27

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO While endocrine therapy (ET) and CDK4/6 inhibitors are the standard for treating ER+/HER2- metastatic breast cancer, patients can become resistant to ET. To overcome these resistance mechanisms, the ELEVATE study examines whether combining elacestrant with ET could help address this unmet need. Here to share the preliminary findings from ELEVATE with Dr. Charles Turck is lead study investigator Dr. Hope Rugo

00:00:00

EMERALD Expert Views: Managing ER+/HER2-, ESR1m mBC...

Oncology and Hematology ·

2024/11/26

Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there’s uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic

00:00:00

Emerging Biomarker Landscape in...

Oncology and Hematology ·

2024/11/12

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Steven Maron, MD, MSc Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it’s important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient’s treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven

00:00:00

Poster Pearl: Comparing the Efficiency of Stool-Based...

Oncology and Hematology ·

2024/10/09

Host: Matt Birnholz, MD For patients at average risk of colorectal cancer (CRC), the United States Preventative Services Task Force recommends screening with either the multi-target stool DNA test or fecal immunochemical test. But in light of new performance data that compared a multi-target stool DNA test and a fecal immunochemical test, a poster presented at the 2024 Digestive Disease Week conference re-evaluated the benefits and harms associated with each test. Tune in to learn more

00:00:00

Poster Pearl: Comparing Endorsed vs. Non-Endorsed CRC...

Oncology and Hematology ·

2024/10/09

Host: Matt Birnholz, MD The United States Preventative Services Task Force endorses multiple screening options for patients at average-risk of colorectal cancer (CRC). These options include colonoscopy, multi-target stool DNA, and the fecal immunochemical test. However, performance data for non-endorsed options like multi-target stool RNA and blood-based screening tests have recently been published. That’s why a recent poster presented at the 2024 Digestive Disease Week conference

00:00:00

Warm Autoimmune Hemolytic Anemia: How Antibody-Based...

Oncology and Hematology ·

2024/09/18

Host: Caroline Piatek, MD Guest: Irina Murakhovskaya, MD Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37oC. Innovative targeted therapies to address wAIHA are emerging, and many are likely to greatly improve patient outcomes when they reach the clinic. Join Drs. Caroline Piatek and Irina Murakhovskaya as they discuss in detail current and emerging non-antibody

00:00:00

From MGUS to Multiple Myeloma: Understanding the...

Oncology and Hematology ·

2024/09/16

Guest: Betsy O'Donnell, MD Plasma cell disorders range from multiple myeloma to the monoclonal gammopathy of undetermined significance (MGUS), which is a benign condition that affects anywhere between 3 and 10 percent of the population starting at age 50. However, about 1 percent of people per year who have MGUS will progress to multiple myeloma. Here to talk about common precursor diseases like MGUS and smoldering myeloma and how they can progress to multiple myeloma is Dr

00:00:00

Insights from ICARUS-Lung01: Efficacy and Safety of...

Oncology and Hematology ·

2024/09/09

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joshua E. Reuss, MD The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss the findings with Dr. Charles Turck is Dr. Joshua Reuss, Assistant Professor in the Department of Medicine at Georgetown University

00:00:00

Navigating the Complexities of Sickle Cell Disease:...

Oncology and Hematology ·

2024/08/19

Host: Jennifer Caudle, DO Guest: Samuel R. Wilson, MD Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology, clinical presentation, burden, and unmet needs of sickle cell disease is Dr. Samuel R. Wilson, Assistant Professor of Medicine in the

00:00:00

Beyond Single-Cancer Screens: Unveiling Progress in...

Oncology and Hematology ·

2024/08/09

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jessie Hsieh, MD Guest: David Isaacson, MD About 70 percent of all cancer-related deaths are associated with cancers that don't have recommended USPSTF screening modalities.1 But the good news is that adding multicancer early detection (MCED) testing to usual care screenings could help address this gap and potentially improve outcomes by screening for more cancer types. Joining Dr. Charles Turck to share their experiences with

00:00:00

Enhancing Treatment Strategies With Molecular...

Oncology and Hematology ·

2024/08/08

Host: Josep Tabernero, MD, PhD Guest: Sara Lonardi, MD Guest: Zev A. Wainberg, MD Join us for a CME online broadcast replay of a live satellite symposium from ESMO GI 2024, where experts discuss strategies to overcome barriers to implementing a collaborative, biomarker-based approach in precision oncology for HER2+ GI cancers. Learn how to individualize therapeutic planning and sequencing for patients with HER2+ gastric/GEJ cancers and improve response and durability in mCRC

00:00:00

Chairperson Perspective: Practice-Changing Strategies...

Oncology and Hematology ·

2024/07/23

Host: Matthew S. Davids, MD, MMSc Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address

00:00:00

Delivering Guideline-Based Hepatocellular Carcinoma...

Oncology and Hematology ·

2024/07/23

Host: Jody Takemoto, PhD Guest: Robert Wong, MD Since the guidelines for diagnosing and treating hepatocellular carcinoma are often lengthy and complicated, it can be difficult for clinicians to stay up to date on the current recommendations and implement them in clinical practice. That’s why a team with the HCC Steering Committee of the Chronic Liver Disease Foundation developed a web-based, interactive tool that incorporates current guideline recommendations to help clinicians

00:00:00

Myeloma Matters: Prevention and Management of...

Oncology and Hematology ·

2024/07/18

Host: Jesus G. Berdeja, MD Guest: Nicholas G. Barkemeyer, MPAS Guest: Ajai Chari, MD Guest: Harvey Church Guest: Amy Gebhardt Guest: Steven Morrow This activity is not accredited for CME/CE credit. This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper

00:00:00

Emerging Frontiers: CAR T-Cell Therapy for Solid...

Oncology and Hematology ·

2024/07/16

Host: Matt Birnholz, MD Guest: Saad Kenderian M.B, Ch.B CAR T-cell therapy has been revolutionary in the treatment of blood cancers like chronic lymphocytic leukemia and multiple myeloma, and according to recent research, this therapeutic approach may also help patients with thyroid cancer. However, there are several challenges associated with applying this technology to target solid tumors in thyroid cancer, like tumor heterogeneity and resistance. Joining Dr. Matt Birnholz to

00:00:00

Optimizing Biomarker Testing to Guide Treatment...

Oncology and Hematology ·

2024/07/16

Guest: Elizabeth Montgomery, MD Guest: John L. Marshall, MD This 1.0-credit activity provides oncology clinicians with practical insights into the importance of biomarker testing in patients diagnosed with metastatic colorectal cancer (mCRC), optimizing biomarker testing procedures, and the role of biomarkers in guiding treatment selection. Case vignettes will provide the basis for expert faculty discussions that explore ways to address common barriers to biomarker testing,

227 results

Oncology and Hematology

All Episodes

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe